Biological Agent Trials for Psoriasis Rarely Include Patient Images
FRIDAY, Dec. 29, 2023 -- Few randomized controlled trials involving biological agents for psoriasis treatment include patient images, according to a review published online Nov. 15 in the Journal of Dermatological Treatment.
Sam Polesie, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 29, 2023 Category: Pharmaceuticals Source Type: news
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small …
In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores In an acute psoriasis model, data show reductions in tissue IL-17A mRNA and improvement in clinical disease markers…#il17a #commensurate #jamesferguson #mdmatinas #lnc #pcr #dss #il17amrna #matinasbiopharma #mat2203 (Source: Reuters: Health)
Source: Reuters: Health - December 27, 2023 Category: Consumer Health News Source Type: news
Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in Japan
Adalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 22, 2023 Category: Pharmaceuticals Source Type: news
Paradoxical Eczema Risk Low With Biologic Psoriasis Tx Paradoxical Eczema Risk Low With Biologic Psoriasis Tx
Ali Al-Janabi, MA, and associates found that 273 (1%) of approximately 25,000 drug exposures in 13,699 biologic-treated patients with psoriasis were associated with paradoxical eczema.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 22, 2023 Category: Consumer Health News Tags: Dermatology Source Type: news
Reducing CVD Morbidity and Mortality in Psoriasis and PsA Reducing CVD Morbidity and Mortality in Psoriasis and PsA
Only a minority of patients with psoriatic disease know about their increased risks.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 20, 2023 Category: Dermatology Tags: Dermatology Source Type: news
Types of psoriasis
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - December 14, 2023 Category: Consumer Health News Source Type: news
How Do You Select Systemic Therapy for Your Psoriasis Patients?
(MedPage Today) -- In this exclusive MedPage Today video, Richard Warren, MBChB, PhD, professor of Dermatology at the University of Manchester in England, explains how he approaches selecting systemic therapy and what he considers to be the "mainstay... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - December 12, 2023 Category: Dermatology Source Type: news
Bimekizumab Promising for Palmoplantar Pustular Psoriasis Bimekizumab Promising for Palmoplantar Pustular Psoriasis
PPP is a type of pustular psoriasis that remains a treatment challenge, and available treatments for palmoplantar plaque psoriasis with pustules also " remain unsatisfactory. "MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 12, 2023 Category: Dermatology Tags: Dermatology Source Type: news
Deucravacitinib Improves Joint Symptoms in Psoriatic Arthritis
(MedPage Today) -- Patients with plaque psoriasis who screened positive for psoriatic arthritis in the POETYK PSO-1 and POETYK PSO-2 trials reported greater improvements in joint activity and joint pain scores when treated with deucravacitinib... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - December 6, 2023 Category: Dermatology Source Type: news
Analysis Supports Link Between Psoriasis and OSA Analysis Supports Link Between Psoriasis and OSA
Several hypotheses may explain the connection, such as the presence of inflammatory mediators and nocturnal cytokine secretion, according to the authors.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 4, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Tapinarof Effective for AD in Patients as Young as 2 years Tapinarof Effective for AD in Patients as Young as 2 years
Tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, was approved in 2022 for treating plaque psoriasis in adults.MDedge News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - November 29, 2023 Category: Pediatrics Tags: Dermatology News Source Type: news
Nail Psoriasis in Black Patients Often Overlooked Nail Psoriasis in Black Patients Often Overlooked
Underrepresentation of Black patients with psoriasis in trials and textbooks might partially explain why clinicians are slow to recognize nail involvement, even after psoriasis has been diagnosed.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 28, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
A Pill for Psoriasis: The Latest Oral Medications A Pill for Psoriasis: The Latest Oral Medications
Kylee Wang and Dr Jennifer Soung give an overview of the current oral therapies for psoriasis, plus a look at potential new agents.Medscape Dermatology (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 28, 2023 Category: Dermatology Tags: Dermatology Commentary Source Type: news
New Data on TYK2 Inhibitors for Psoriasis, Psoriatic Arthritis
(MedPage Today) -- Studies were presented at the American College of Rheumatology (ACR) annual meeting on the safety and efficacy of two oral tyrosine kinase 2 (TYK2) inhibitors -- TAK-279, a selective TYK2 inhibitor in patients with active psoriatic... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - November 22, 2023 Category: Dermatology Source Type: news
